Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Anju Ghangurde
The Indian contract development and manufacturing organization (CDMO) Piramal Pharma Solutions (PPS) expects to grow its pool of “preferred partnerships” that includes a mix of both biotechs and large pharma. In an interview with Scrip, CEO Vivek Sharma outlined the value of such “symbiotic” relationships and how PPS is focused on quality as a culture rather than purely limiting it to inspection clearance and product approvals.
Further evidence of the impact of pricing pressure in the US was provided when Sun Pharma reported a sharp fall in profits in Q2 (although it beat the expectations of some analysts). Sun also expects a delay in EU approval for its late stage psoriasis asset, tildrakizumab, but US approval timelines appear unchanged, at least for now.
Lara Bezerra moves from turbulent Venezuela to head Roche in India. Scrip highlights what the incoming Roche boss might expect on the generally peaceful yet complex Indian market.
Bayer presses on with legal action to fend off alleged infringers of its patent on Xarelto in India. A hearing is expected shortly in one such case, which seemingly includes a settlement option. The German multinational also remains engaged in a keenly contested and controversial case around India’s Bolar exemption provision - the experimental use or early working exception.
Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.
Glenmark reported subdued Q2 earnings, with the management predicting that the US business environment could stay challenging for at least two years. The firm, though, was upbeat on the potential of certain R&D assets, with a monoclonal antibody seen as “most promising” from an out-licensing perspective and a combination for seasonal allergic rhinitis set for a US NDA filing early next year.